Translating laboratory discoveries into clinical benefit for patients with breast cancer increasingly depends on combining ...

Oral vitamin C improved OS in patients with CCUS or lower-risk myeloid malignancies in the EVITA trial despite missing the clonal growth primary end point. Although the phase 2 EVITA trial ...

Sone-Ve significantly improved OS vs investigator’s choice in previously treated CLDN18.2-positive gastroesophageal carcinoma ...

The next-generation KRAS G12C inhibitor divarasib significantly prolonged progression-free survival (PFS) and overall ...

Congress, 3 proffered paper presentations examined treatment strategies across the renal cell carcinoma (RCC) continuum. LITESPARK-012: in the frontline setting, adding belzutifan (Welireg) or ...

Based on data from the phase 3 SAFFRON trial, osimertinib plus savolitinib may establish a new global standard of care in this EGFR-mutated NSCLC population. Data from the phase 3 Krascendo 1 trial ...

Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal ...

Long-term PEACE-1 data showed that adding abiraterone acetate plus prednisone to standard of care extended median OS by 1.5 years in de novo metastatic CSPC. At the 2026 European Society for Medical ...

Adding ribociclib (Kisqali) to a nonsteroidal aromatase inhibitor (NSAI) produced an overall survival (OS) benefit vs NSAI ...

In October 2026, the Vatican announced that Pope Leo XIV had undergone a right lower lobectomy to remove a lung nodule that ...

Adding pembrolizumab to carboplatin and etoposide improved response rates and OS vs chemotherapy alone in metastatic NEPC in ...

The FDA assigned a PDUFA date of June 14, 2027, to UGN-103, for the treatment of recurrent low-grade intermediate-risk ...